Zoetis price target lowered to $140 from $155 at Stifel

Stifel lowered the firm’s price target on Zoetis (ZTS) to $140 from $155 and keeps a Hold rating on the shares. Something seemingly had to give, the firm says. Stifel notes Zoetis revised 2025 revenue lower and its 2026/2027 estimates, which were already below Street, move lower. While Zoetis remains upbeat about 2026 growth prospects, the second half of 2025 volume likely exits at 0% growth. Looking forward, the anchor from Librela likely eases but share pressures in Dermatology, and to a lesser extent, Parasiticides, may get worse. The firm awaits its upcoming International and U.S. AH survey diligence to further assess share trends across key franchises.